Skip to content
10-K

Annual Report

Adhera Therapeutics, Inc.

0001493152-23-010160

← back to feed
Filed
Mar 31, 2023 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2022 · Mar 31, 2023 3.18M sh
Stock Repurchased FY 2022 · Dec 31, 2022 $2K
Operating Cash Flow FY 2022 · Dec 31, 2022 −$1.42M
Operating Cash Flow FY 2022 · Dec 31, 2021 −$665K
Cash And Equivalents FY 2022 · Dec 31, 2022 $32K
Stockholders Equity FY 2022 · Dec 31, 2022 −$22.19M
Stockholders Equity FY 2022 · Dec 31, 2021 −$25.11M
Stockholders Equity restated FY 2022 · Dec 31, 2020 −$14.74M
Current Liabilities FY 2022 · Dec 31, 2022 $22.27M
Current Liabilities FY 2022 · Dec 31, 2021 $25.3M
Total Liabilities FY 2022 · Dec 31, 2022 $22.27M
Total Liabilities FY 2022 · Dec 31, 2021 $25.3M
Current Assets FY 2022 · Dec 31, 2022 $79K
Current Assets FY 2022 · Dec 31, 2021 $196K
Total Assets FY 2022 · Dec 31, 2022 $79K
Total Assets FY 2022 · Dec 31, 2021 $196K
Eps Basic FY 2022 · Dec 31, 2022 −$1.18
Eps Basic FY 2022 · Dec 31, 2021 −$12.84
Net Income FY 2022 · Dec 31, 2022 −$2.11M
Net Income FY 2022 · Dec 31, 2021 −$6.35M
Operating Income FY 2022 · Dec 31, 2022 −$1.62M
Operating Income FY 2022 · Dec 31, 2021 −$674K